Anti-tumor pharmaceutical composition and application thereof

An anti-tumor drug and composition technology, applied in the field of biopharmaceuticals, can solve problems such as limited gene capacity and hidden dangers of biological safety, and achieve the effects of reduced growth, weak toxicity, and reduced survival rate

Active Publication Date: 2021-02-05
THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Viral vectors have high transfection efficiency, but the capacity of viral vectors to load genes is limited, and they have strong immunogenicity, which poses potential biological safety hazards

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor pharmaceutical composition and application thereof
  • Anti-tumor pharmaceutical composition and application thereof
  • Anti-tumor pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] An anti-tumor pharmaceutical composition, comprising 0.1 mg calcium alendronate and 50 μl anti-EpCAM / CD3 bispecific antibody gene.

[0036] Wherein the preparation of calcium allen phosphate comprises the following steps: 0.1gCaCl 2 2H 2 O dissolved in 40mL of distilled water to form an aqueous solution of soluble calcium salts, 0.33g sodium alendronate was dissolved in 40mL of distilled water to form an aqueous solution of sodium allenphosphate, and the aqueous solution of soluble calcium salts was added to the aqueous solution of sodium allenphosphate and mixed thoroughly Form a mixture, use NaOH solution to adjust the pH value of the mixture to 5.5, and heat it in a microwave at 100° C. for 10 min to obtain a white crude calcium allenphosphate product; wash the crude calcium allenphosphate product once with distilled water, Washed twice with absolute ethanol, dried in an oven at 60°C for 24 hours to obtain calcium allen phosphate, and dried for later use.

[0037] ...

Embodiment 2

[0039]An anti-tumor pharmaceutical composition, comprising 0.2 mg of calcium alendronate and 50 μl of anti-EpCAM / CD3 bispecific antibody gene.

[0040] Wherein the preparation of calcium allen phosphate comprises the following steps: 0.1gCaCl 2 2H 2 O dissolved in 40mL of distilled water to form an aqueous solution of soluble calcium salt, 0.4g sodium alendronate was dissolved in 40mL of distilled water to form an aqueous solution of sodium alendronate, and the aqueous solution of soluble calcium salt was added to the aqueous solution of sodium allenphosphate and mixed thoroughly Form a mixture, use NaOH solution to adjust the pH value of the mixture to 4.5, microwave heating at a temperature of 80°C for 10 minutes, and obtain a white crude calcium allenphosphate product; wash the crude calcium allenphosphate product once with distilled water , washed twice with absolute ethanol, dried in an oven at 60°C for 24 hours to obtain calcium allen phosphate, and dried for later use....

Embodiment 3

[0043] An anti-tumor pharmaceutical composition, comprising 0.1 mg of calcium alendronate and 60 μl of anti-EpCAM / CD3 bispecific antibody gene.

[0044] Wherein the preparation of calcium allen phosphate comprises the following steps: 0.2gCaCl 2 2H 2 O is dissolved in 40mL distilled water to form an aqueous solution of soluble calcium salt, 0.45g of sodium alendronate is dissolved in 40mL of distilled water to form an aqueous solution of sodium allenphosphate, and the aqueous solution of soluble calcium salt is added to the aqueous solution of sodium allenphosphate and mixed thoroughly Form a mixture, use NaOH solution to adjust the pH value of the mixture to 6.0, microwave heating at a temperature of 95 ° C for 10 min, and obtain a white crude calcium allen phosphate product; wash the crude calcium allen phosphate product once with distilled water , washed twice with absolute ethanol, dried in an oven at 60°C for 24 hours to obtain calcium allen phosphate, and dried for late...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of biological pharmacy, and particularly discloses an anti-tumor pharmaceutical composition and application thereof. The pharmaceutical composition comprises alendronate calcium and an exogenous gene. The pharmaceutical composition is high in safety, can reduce survival rate of human ovarian cancer cell SKOV3 cells, and reduce growth of tumor cells, buthas weak toxicity to human renal tubular epithelial cells HK2.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to an anti-tumor pharmaceutical composition and its application. Background technique [0002] With the continuous development of gene therapy, there have been two main streams in terms of gene transfer vectors: one is the non-viral vector system; the other is the viral vector system. In the field of gene therapy, viral vectors are the most common type of gene vectors. About 70% of the treatment plans use viral vectors. Viral vectors mainly include various retroviruses, adenoviruses, adeno-associated viruses (AAV), and herpes viruses. , pox virus, etc. This type of viral vector is to introduce foreign genes into host cells by using viruses to infect host cells. Viral vectors have high transfection efficiency, but the capacity of viral vectors to load genes is limited, and they have strong immunogenicity, which poses potential biological safety hazards. [0003] Current...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/54A61K48/00A61K31/713A61K31/711A61P35/00C07F9/38
CPCA61K47/548A61K48/0033A61K31/713A61K31/711A61P35/00C07F9/38Y02A50/30
Inventor 庞俊赵静张士强钱志荣邱妙娟陈俊宗李宾宾黄秀玉
Owner THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap